initi buy pt
one highest growth compani biopharma
ep compound-annual-growth-rate consensu versu biotech large-cap mean
ex-bmrn us pharma mean challeng market
predict growth compani may perform better view
rate buy see continu growth due greater uptak
cf cystic fibrosi patient follow recent approv
trikafta potenti could treat cf patient recent
reimburs agreement major territori includ eu uk spain
australia franc canada remain outstand key overhang
stock potenti price upsid current model symdeko
price trikafta ex-u territori premium symdeko
trikafta ex-u see upsid fv
view investor like stay away
compani due lack diversif diversif come
start anti-trypsin poc data earli multipl
data catalyst pipelin see potenti upsid
believ earli give credit crisper data fetal hemoglobin level
biomark sickl cell diseas scd expect beta-
thalassemia bt model peak unadjust sale aatd
probabl program contribut dcf fv
everi increas probabl add dcf
think global partnership pain could potenti near term
catalyst believ investor give credit
program yet key thesi note compani
complet dose escal non-opioid inhibitor
said plan partner chronic market launch
acut multi-billion dollar market neuropath market
said global partner would want plan run phase believ
partner right dose dont know
current drug drug take forward could affect
time global deal
valuat risk
use dcf arriv pt use discount rate appropri
lower-risk larg cap compani yet diversifi use
termin valu believ compani use capit continu
gener revenu assign probabl pipelin risk poor
uptak reimburs trikafta clinic trial failur lack binari event
tr target
tabl content
risk thesi
initi buy rate pt
vertex high growth compani
overhang behind us vertex pois treat cf patient
strh rational own diversif pipelin readout come
pain could catalyst
risk thesi
model convers faster consensu
investor question tripl combo approv us sever month ahead
pdufa date hurdl uptak drug het-min popul
concern around convers drug onto trikafta
investor question compani demonstr robust efficaci tripl combo
homozyg het-min patient approv switch ex-
us price strategi
investor question current cystic fibrosi indic support vertex
top-line could potenti competit creat overhang stock
investor question base busi continu grow question lot
investor around reimburs ex-u
investor question pipelin earli includ multipl modal impact see
pipelin stock expect semin year accord reshma kewalramani ceo-
investor question past month manag undergon multipl
chang note investor concern around chang manag chang
compani expect chang strategi term bd reimburs ex-u
corrector target anti-trypsin defici current advanc phase develop
clinic data peopl two mutat anticip note potenti peak
page
opportun assign valu model note upsid everi
antitrypsin defici inherit disord caus defici may
caus lung diseas liver diseas accord diseas affect peopl us
eu current cur therapi diseas
approv therapi aatd augment therapi iv infus purifi human
market drug continu unmet need therapi target
lung liver revers damag alreadi done
vertex current develop corrector target aatd first candid current
phase studi data patient expect second candid phase
view global partnership pain franchis could near-term catalyst compani
expect potenti announc view posit phase data inhibitor
differ indic support franchis think investor need see partnership
assign valu program
develop first-gener inhibitor sodium ion channel
subtyp carri pain messag channel target treatment pain due
specif locat sensori neuron
sever compani target sumitomo dainippon
two compani target pain highlight inhibit
success date
data vrtx trial first evid efficaci inhibit compani
shown posit data inhibitor differ indic highlight
aspect challeng demonstr efficaci across multipl differ type pain
mechan
page
risk thesi
key risk thesi includ clinic trial failur poorer expect uptak trikafta poorer
reimburs price declin lack global partnership
page
bull/bear srth casebul casebear casefair valuepric target valu valu us revenu us revenu us revenu cf patient vertex drug us cf patient vertex drug us cf patient vertex drug us peakconvers patient trikafta patient trikafta patient trikafta price us price us price us eu revenu eu revenu eu revenu cf patient vertex drug cf patient vertex drug peak cf patient vertex drug peak ex-u trikafta ex-u price in-lin symdekotrikafta ex-u price premium symdekotrikafta price ex-u in-lin symdekono credit probabl success peak opportun trypsin defici credit pipelinedcf base model discount rate termin growth ratedcf base model discount rate termin growth ratedcf base model discount rate termin growth rate vertex pharmaceut incorpor
initi buy rate pt
one highest growth compani biopharma ep compound-annual-growth-rate
consensu versu biotech large-cap mean ex-bmrn us pharma mean
challeng market predict growth compani may perform better
rate buy see continu growth due higher penetr cf cystic
fibrosi patient popul follow recent approv trikafta potenti
could treat cf patient recent reimburs agreement major
territori includ eu uk spain australia franc canada remain outstand
key overhang stock
view investor like stay away compani due lack
diversif diversif come start anti-trypsin poc data earli
multipl data catalyst pipelin see potenti upsid believ
earli give credit crisper data fetal hemoglobin level biomark sickl cell
diseas scd expect beta-thalassemia bt
think global partnership pain could potenti near term catalyst
believ investor give credit program yet key thesi
note compani complet dose escal non-opioid
inhibitor said plan partner chronic market launch
acut multi-billion dollar market neuropath market said global
partner would want plan run phase believ partner
right dose dont know current drug drug take forward
could affect time global deal
page
vertex high growth compani
note year compound-annual-growth-rate top bottom-lin respect
strh research compani report factset
analysi also indic one highest growth compani biopharma
year ep compound-annual-growth-rate consensu versu biotech mean ex-bmrn us pharma
figur ep price-to-earnings analysi larg cap us pharma
page
overhang behind us vertex pois treat cf patient
recent approv trikafta tripl combin potenti treat
cystic fibrosi patient vertex continu growth domin cf analysi indic
one fastest grow biopharma compani
octob almost month ahead pdufa date fda approv vrtx tripl
combin drug trikafta drug approv patient older least one
mutat cftr drug approv age yet cf patient
estim elig drug also price trikafta higher street
anticip view street assum lower price instead compani price
price kalydeco kalydeco highest price drug compani sell cf
previous approv drug kalydeco/orkambi/symdeko alreadi target major cf
patient approv immedi make drug avail new patient us
difficult-to-treat het-min mutat accord compani key hurdl capac cf
clinic abl process patient expect launch could take longer reach
peak versu previou launch due hurdl
strh rational own diversif pipelin readout come
despit growth potenti investor might stay away compani wait
pipelin beyond cf evolv depend singl franchis could make investor
nervou vrtx top-line current depend sole cf franchis
addit potenti catalyst pain franchis note key data readout expect
includ phase data readout aatd phase data readout crispr
therapeut crsp nr collabor sickl cell diseas beta-thalassemia howev
sure much credit investor would assign program even posit data
data expect earli otherword data show strong signal investor may begin
assign credit howev thesi conting decent data plu revenu ep
growth event could less binari investor expect data isnt stellar earli
phase trial expect enrol patient serum level primari endpoint
assign credit program note potenti peak opportun note
everi peak sale add dcf
sickl cell beta-thalassemia trial compani note partner crsp expect provid
initi readout trial manag note dozen site open trial
site enrol expect see safeti data engraft cell hemoglobin level
biomark
page
strh research compani report
pain could catalyst
global partnership pain could potenti catalyst pan
yet develop drug pain shown posit data small phase studi across
multipl pain indic chronic pain potenti multi-billion dollar market compani
indic interest establish global partnership could get investor assign
valu program compani current run dose find phase studi follow
could potenti announc howev recent convers manag
got sens shift focu rest pipelin sure mean second
gener pain drug need establish partnership recent financi
result call compani note next-gener pain drug enter clinic
potenti upsid global pain partnership much credit would investor assign even
announc global partnership think would upsid stock investor
would assign valu program time dont know deal could look like
much upsid would come announc
pain landscap complex competit dont know key hurdl partnership
addit even instanc global partnership investor concern
diversif may find enough pain market signific note also
competit despit concern around opioid crisi cost perspect gener opioid
like make tougher price drug premium
page
kidney diseasesphas data initi phase studi evalu design inhibit function causal genet factor fsg proteinur kidney diseas vertex also advanc multipl inhibitor preclin data global partnership announc fibrosisphas studi combin tezacaftor data fda fast track data phase studi antitrypsin defici aatd phase data fda fast track april phase studi patient initi data expect antitrypsin defici aatd phase data readoutnot availablereceiv track design fibrosisphas dose-rang studi data evalu once-daili potenti support potenti phase develop once-daili tripl combin diseasephas global studi data fda fast track januari first patient scd us dose thalassemiaphas global studi data fda fast track april first patient beta thalassemia dose timelin on-going studi vertex pharmaceut incorpor
pt deriv use dcf use termin valu account use capit develop
new product diversifi busi use discount rate see appropri less
figur pt deriv dcf
strh research compani report
risk thesi
key risk thesi includ clinic trial failur poorer expect uptak trikafta poorer
reimburs price declin lack global partnership
page
base work present valu termin growth valu npv termin valu total revenu calcul free discount debt debt share vertex pharmaceut incorpor
model convers faster consensu
recent approv tripl combin trikafta us expect approv eu
well reimburs agreement cover major market continu ww
domin cf trikafta potenti treat cf patient time
strh research compani report
in-lin compani expect model patient kalydeco orkambi symdeko switch
trikafta note aggress street
figur convers legaci drug trikafta year strh versu consensu
strh research compani report
page
investor question tripl combo approv us
sever month ahead pdufa date hurdl uptak
drug het-min popul concern around convers
drug onto trikafta
strh take given qualiti data tripl combin across board especi
hard-to-treat het-min patient expect uptak hem-min popul high
eventu expect compani convert major patient trikafta
kalydeco orkambi symdeko approv treatment patient
homozyg mutat gate function mutat residu function mutat recent data
tripl combo symdeko demonstr improv vs placebo
benefit hard-to-treat het/min popul week improv vs
symdeko homozyg popul
trikafta approv almost month ahead pdufa date vertex anticip submit
tripl combo approv anticip view robust data
signific unmet need het/min popul support approv ex-u territori
figur summari data vertex product cf
strh research compani report
addit despit controversi around price particularli ex-u territori long-term
studi shown signific improv qualiti life cf patient
figur valu treat cf hc system larg
page
mutationtri nameexpand trial trial trial year year year year year year year differ drug pbo mean absolut chang baselin week absolut chang baselin cfq-r respiratori domain score week risk pulmonari chang sweat chlorid week combo mutationkalydeco approv orkambi homozygoussymdeko homozygous/residu function vertex pharmaceut incorpor
investor question compani demonstr robust efficaci
tripl combo homozyg het-min patient
approv switch ex-u price strategi
strh take talk compani around price note expect eventu convert
major patient tripl combo model switch orkambi symdeko tripl
period year
data tripl combo robust expect continu domin cf space
compani strong ip protect approv drug rang
drug develop expect ip protect well beyond
figur ip vertex drug
compani report strh research
compani expect patient eventu switch tripl combo expect price
accordingli us price use kalydeo price assum discount eu
know price higher price reimburs upsid
model switch orkambi symdeko tripl period year
page
investor question current cystic fibrosi indic
support vertex top-line could potenti competit creat
overhang stock
strh take base research see signific impact vrtx top-line
competit near futur howev discount competit note
abbv glpg program worth keep eye
highlight key point support view-
view establish leader cystic fibrosi space small commun
well entrench patient advocaci group well specialti doctor treat
cf expect benefit brand loyalti
research indic sever compani investig drug cf
significantli ahead competitor term clinic stage also reimburs process
particularli ex-u challeng even note late stage studi
shown summari tabl
compani galapago glpg nr proteostasi pti nr
develop doublet triplet combo corrector potenti treatment cf
note lack success date help continu maintain lead cf
howev discount competit late last year took galapago cystic
fibrosi program goal develop best-in-class tripl combo therapi cf remind
glpg orkambi led chang glpg in-hous tripl combo
show improv current conduct trial
patient homozyg patient treat alon combin
potenti corrector studi initi septemb day studi data
like
figur timelin competitor cf readout
page
beyond develop small molecul drug target cf also enter collabor
crispr discoveri develop gene edit target cf option
exclus licens result therapeut target
figur summari competitor vertex
strh research compani report
page
compani product nametargetphas developmentabbvi fibrosi transmembran conduct regul cftr phase iabbvi fibrosi transmembran conduct regul cftr phase iabbvi fibrosi transmembran conduct regul cftr phase iiastrazeneca sodium channel enac phase igalapago fibrosi transmembran conduct regul cftr phase iigrifol hc antitrypsin iigalapago fibrosi transmembran conduct regul cftr phase iigalapago fibrosi transmembran conduct regul cftr phase iikamada ltd aerosol antitrypsin antitrypsin iigalapago fibrosi transmembran conduct regul cftr phase igalapago fibrosi transmembran conduct regul cftr phase igalapago fibrosi transmembran conduct regul cftr phase icorbu pharmaceut hold inc lenabasum anabasum resunab cannabinoid receptor iiimperi colleg fibrosi transmembran conduct regul cftr phase iiparion scienc sodium channel enac phase iiproqr eluforsen fibrosi transmembran conduct regul cftr phase iproteostasi fibrosi transmembran conduct regul cftr phase i/iiproteostasi fibrosi transmembran conduct regul cftr phase ivertex pharmaceut fibrosi transmembran conduct regul cftr registrationvertex pharmaceut inc lumacaftor fibrosi transmembran conduct regul cftr phase iiivertex pharmaceut inc tezacaftor fibrosi transmembran conduct regul cftr phase iiivertex pharmaceut fibrosi transmembran conduct regul cftr phase iiivertex pharmaceut fibrosi transmembran conduct regul cftr phase iiivertex pharmaceut inc deuter ivacaftor d-ivacaftor fibrosi transmembran conduct regul cftr phase iivertex pharmaceut fibrosi transmembran conduct regul cftr phase iivertex pharmaceut fibrosi transmembran conduct regul cftr phase iivertex pharmaceut fibrosi transmembran conduct regul cftr phase ii vertex pharmaceut incorpor
investor question base busi continu grow
question lot investor around reimburs ex-u
strh take absenc competit near-term label geograph expans
drug robust tripl data expect support ex-u reimburs
expect base busi continu grow
compani continu add label expans across board approv drug tripl
combin trikafta recent approv homozyg well het-min popul
latter difficult treat patient anticip approv drug eu
approv expect rest world expect vertex drug abl treat
figur reimburs global took time drug
strh research compani report
page
patient sever mutat year sever mutat year sever mutat month least one mutat homozyg homozyg homozyg homozyg residu function homozyg residu function homozyg het/minim function datemaa submit vertex pharmaceut incorpor
figur summari reimburs agreement date
franc vertex get paid symdeko contract place recogn
dont know final price
page
countri datelatest updatenorth americausanaal three approv drug recommend orkambi reimburs cf approv health canada yet put thought cadth review process public reimburs reimburs year approv march eu avail patient year orkambi elig patient initi orkambi continu orkambi earli access program paid patient wont recogn revenu patient finalreimbursementagr secur manag note product discuss french author secur nh england access licens cf reimburs agreement ireland orkambi futur cf access agreement scottish govern orkambi agreement orkambi itali contract denmark current futur cystic fibrosi govern approv nation reimburs orkambi lumacaftor/ivacaftor symkevi tezacaftor/ivacaftor combin kalydeco fulli reimburs year straight reimburs deal orkambi year homozyg portfolio type ofreimbursementagr announc sweden june provid immedi access orkambi framework rapid access futur agreement reach agreement reach reimburs orkambi agreement australia reimburs symkevi elig patient orkambi homo children certain cftr mutationscountri orkambi/symdeko reimburs canada belgium portug poland czech republ russian feder switzerland hungari turkey ukrain new zealand south africa vertex pharmaceut incorpor
investor question pipelin earli includ multipl modal
impact see pipelin stock expect semin
year accord reshma kewalramani ceo-in-wait
strh take note pipelin earli contribut top-line
view approv tripl combo label geograph expans tripl
reimburs process ex-u like continu catalyst stock look
beyond cf note key pipelin catalyst program pain
figur summari vertex pipelin
compani report strh research
page
productindicationcatalysttimingnotesymdeko/symkevicyst fibrosiseu regulatori file treat children year cf due two copi mutat cftr gene one copi plu one residu function mutat plan submit snda alreadi receiv approv patient yr tripl fibrosismaa submiss treatment patient yrscf tripl fibrosispotenti commerci nda fda juli receiv prioriti kidney diseasesphas data initi phase studi evalu design inhibit function causal genet factor fsg proteinur kidney diseas vertex also advanc multipl inhibitor preclin data global partnership announc fibrosisphas studi combin tezacaftor data fda fast track data phase studi antitrypsin defici aatd phase data fda fast track april initi dose rang studi aatd patient two mutat antitrypsin defici aatd phase data readoutnot availablereceiv track design fdacf tripl fibrosisphas data readoutnot availablecf due two copi mutat cftr gene one copi plu one residu function mutat children age fibrosisphas dose-rang studi data evalu once-daili potenti support potenti phase develop once-daili tripl combin diseasephas global studi data fda fast track januari first patient scd us expect dose thalassemiaphas global studi data fda fast track april first patient beta thalassemia dose activitysemma merger acquir semma goal develop cur cell-bas treatment type diabet seema receiv cash becom separ oper subsidiari vertex deal expect leadership transitionapril jeffrey leiden transit role execut chairman effect april dr reshma kewalramani appoint new chief execut offic dr leiden serv execut chairman timelin on-going studiescompani catalyst vertex pharmaceut incorpor
figur summari vertex deal
strh research biocenturi
page
companiesheadlined deal typetot deal valueribometrix licensor inc license vertex ribometrix establish strateg collabor discov develop rna-target small molecul commerci seller buyer vertex acquir semma goal develop cur cell-bas treatment type ag licensor inc license crispr grant vertex exclus world-wide right current futur ip cover technolog endonucleas singl doubl cut guid rna adeno-associ viral vector develop dmd gene edit commerci inc buyer exon inc seller acquir exon inc inc licensor inc license partner kymera develop target small molecul protein research product licens inc license merck kgaa licensor merck kgaa grant exclus right two dna damag respons ddr inhibitor target dna-depend protein kinas dna-pk gene edit applic six undisclos commerci licens inc license arbor biotechnolog inc licensor partner arbor biotechnolog util arbor protein biodiscoveri platform discov develop protein tool gene-edit commerci licens inc research partner arbor biotechnolog inc research partner vertex enter research collabor arbor biotechnolog discov novel protein advanc discoveri gene-edit develop inc license genom plc licensor genom partner target discoveri deal treat undisclos seriou commerci licens inc license q-state bioscienc inc licensor q-state bioscienc partner develop drug use q-state optopatch commerci licensex-chem inc licensor inc license x-chem partner discov small molecul undisclos target implic sever genet research product licens option inc seller inc buyer purchas cystic fibrosi program includ cash front pipelin platform inc licensor merck kgaa license grant merck exclus world-wide right four cancer commerci pbc license inc licensor vertex grant trek world-wide develop commerci right lomibuvir merimepodib commerci licens inc research partner inc research partner vertex partner discov develop mrna therapeut cystic fibrosi research product licens llc license inc licensor vertex grant spero world-wide right vertex undisclos antibacteri commerci licenseenterom bioscienc license inc licensor vertex grant enterom exclus world-wide right small molecul antagonist bacteri fimbrial adhesin fimh treat inflammatori bowel diseas commerci licensegenom plc licensor inc license genom grant vertex non-exclus right genom analysi interpret softwar genome-phenom databas develop inc research partner crispr ag research partner vertex expand partnership crispr discov develop treatment use crispr gene edit technolog treat duchenn muscular dystrophi dmd myoton dystrophi type research product licens inc license parion scienc inc licensor parion grant vertex exclus world-wide right portfolio enac inhibitor treat cystic fibrosi pulmonari commerci incorpor
recent year acceler effort invest new partnership acquisit senior
manag talk cash result provid plenti option build
pipelin bd
talk manag pipelin key take-away messag pipelin
develop diversifi beyond cf differ modal includ add
toolkit could util investig diseas select targets/ind
expect base strategi describ previous
note pipelin earli stage asset develop outsid cf pain kidney
diseas one near-term catalyst
degrad cur cell-bas treatment type diabet rna-target small molecul
therapeut platform talk senior manag learn compani technolog
platform agnost wide varieti technolog platform involv
either acquisit partnership consid addit vrtx toolkit investig
diseas interest acquisit expect integr technolog pipelin
well scientif personnel expertis strategi integr
unlik expand intern forc work program
manag reiter multipl time strategi select targets/ind develop
drug highlight earli stage pipelin product fit strategi
figur summari earli stage vertex pipelin
strh research compani report
page
indicationtargetcaus anti-trypsin anti-trypsinmut gene encod lead shortag abnorm form protein either shown caus symtpom diseas differ degreeslevel serumsickl cell diseasehemoglobinmut beta globin gene caus format misfold hemoglobin lead rbc sickle-shapedhemoglobin levels/rbc countbeta-thalassemiahemoglobinmut beta chain hemoglobin lead reduc product hemoglobin consequ anemiahemoglobin levels/rbc kidney diseasesapolipoprotein variant found peopl west african origin shown correl increas risk kidney diseas function unknown duchenn muscular dystrophydystrophinprogress muscl degener caus alter protein call dystrophin dystrophin levels/muscl functionmyoton dystrophi type caus expans ctg repeat non-cod region dmpk lead muscl weak east myotonia cataract often cardiac conduct abnormalitiesunknown incorpor
investor question past month manag
undergon multipl chang note investor concern around
chang manag chang compani expect
chang strategi term bd reimburs ex-u etc
strh take spoke reshma kewalramani ceo-in-wait charl cfo
ream head busi develop key takeaway compani
continu follow strategi establish year ago support cf
franchis one innov select target base causal human biolog
presenc high fidel biomark focu indic specialti forc
takeaway research strategi senior manag highlight strategi choos
project note focus diseas area valid target
address causal biolog target valid gain-of-funct loss-of-funct
data drug discoveri test support translat assay could help predict
potenti drug provid rapid path registr develop commerci
transform medicin near cur cur outcom diseas area
commerci transform drug specialti forc focus particular
figur descript vertex strategi innov
page
takeaway reimburs strategi
continu negoti territori histor challeng
reimburs busi countri formal
reimburs countri
manag note continu support patient advoc remind previous
held back clinic trial countri franc
spain franc make progress sens momentum
one key strategi reimburs ex-u continu portfolio arrang
earn call ceo noted-
think one drive factor behind govern interest portfolio
arrang rapid progress see make develop treatment
treat underli caus diseas patient ye that
one compel thing govern around world theyv
interest see rate progress make good result
see patient that certainli strong drive
want talk portfolio type arrang
takeaway see compani evolv particular focu bd
import thing innov make differ signific focu
intern develop well cfo note opex spent also
anticip signific opex invest earli
compani continu activ bd front manag note
urgenc bd bd strategi also follow intern research strategi
focu causal biolog translat model good chemistri focu unmet need
preclin late stage believ dont offer much latter
need buy revenu also econom target former
consid chemistri compani marri biolog expertis
modal agnost
page
corrector target anti-trypsin defici current
advanc phase develop clinic data peopl two
mutat anticip note potenti peak opportun
assign valu model note upsid
everi peak sale
antitrypsin defici inherit disord caus defici
may caus lung diseas liver diseas accord diseas affect
peopl us eu current cur therapi diseas
caus defici protein produc mostli liver within
hepatocyt macrophag
one primari circul serum anti-proteas human serv inhibit
varieti serin proteinas
primari function protect lung neutrophil elastas also inhibit number
metallo-proteinas pro-inflammatori pro-apoptot molecul
healthi peopl neutrophil elastas releas fight infect enzym
digest damag age cell bacteria promot heal
trap destroy neutrophil elastas uncheck attack healthi lung tissu
aatd caus mutat gene pi homozyg state mutat lead
sever defici result either lung diseas caus loss anti-proteas
function liver diseas toxic gain function z-aat mutant protein
approxim genet form diseas discov subject
sever defici like level serum mm pi zz
genotype/phenotyp genotyp due point mutat gene code
result misfold protein impair secret hepatocyt primari sourc
synthesi accumul misfold protein hepatocyt
page
approv therapi aatd augment therapi iv infus purifi
human market drug continu unmet need
therapi target lung liver revers damag alreadi done
figur competit landscap aatd
strh research biocenturi compani report
patient us eu less ww patient diagnos
figur signific opportun still remain increas diagnosi aatd patient
page
compani nameproducttargettyp therapi aspect diseas targetedphas developmentkamada ltd glassia kamada alpha inhibitor antitrypsin elastaselogic/ deficiencymarketedkamada ltd glassia kamada alpha inhibitor antitrypsin elastaselogic/emphysemamarketedgrifol prolastin proteinas antitrypsin elastaselogic/ deficiencymarketedgrifol prolastin-c deficiencymarketedbaxt healthcar corparalast np inhibitor antitrypsin elastaselogic/congenit defici clinic evid emphysemamarketedcsl behringzemaira inhibitor antitrypsin elastaselogic/chron augment mainten therapi clinic evid emphysemamarketedkamada ltd aerosol antitrypsin inhal antitrypsin antitrypsin deficiencyregistrationalnylam antitrypsin i/iiarrowhead antitrypsin deficiencyphas iarrowhead antitrypsin deficiencyphas ivertex antitrypsin molecul corrector/ deficiencyphas antitrypsin molecul corrector/ deficiencyphas viru aav /hepat preclinicalinhibrx protein/ deficiencypreclinicalappli genet technolog applicableadeno-associ viru aav deficiencypreclin vertex incorpor
vertex current develop corrector target aatd first candid
current phase studi data patient expect second candid
phase healthi volunt studi
aatd fit mold target indic similar mani way cf
like cf protein fold disord caus mutat singl gene
patient one common mutat result life shorten system
complic primarili lung also liver
mutant protein two issu firstli well fold liver lead liver
diseas secondli secret blood caus defici lung protect henc
compani develop seri corrector help liver fold
properli help secret well folder protein serum
compani also develop multipl cell line test corrector well mous
model mutat efficaci level measur surrog biomark
serum level function serum function
manag note believ crack biolog matter
combin chemistri
goal corrector would bring circul level seen carrier
preclin data show treatment corrector lead serum
level within carrier rang reduc level misfold toxic protein liver
figur preclin data indic potenti address aatd patholog
page
compani advanc portfolio small molecul corrector aatd first
candid second poc data expect
earn call compani note initi trial
patient aatd data expect trial consist multipl dose escal
compani also note serum level endpoint trial
note approach creat portfolio molecul singl one compani
follow strategi next-gen corrector cf
follow phase trial healthi volunt data present
compani move drug poc studi clinic
drug portfolio current phase trial healthi volunt
phase data catalyst stock view bar bring level
carrier rang street current give credit program
preclin data compani indic treatment increas level carrier
zone key question whether data seen preclin model translat patient
figur normal rang level
figur level diseas
american thorac societi strh research
page
genotypeeas stateserum antigen umcarri piss pimz umhomozyg pizz defici um although mainten blood serum level antigen measur postul provid therapeut relev antineutrophil elastas protect proven american thorac societi guidelin approach patient sever hereditari defici respir prolastin packag insert zemaira packag insert vertex pharmaceut incorpor
assign valu program model note potenti peak opportun
corrector peak sale add dcf
figur revenu build aatd strh model
strh research compani report
page
defici us popul defici diagnosi patient mutat target patient popul rate treat corrector price sale defici eu popul defici diagnosi patient elig patient popul rate treat annual price sale corrector ww sale vertex pharmaceut incorpor
view global partnership pain franchis could near-
term catalyst compani expect potenti announc
view posit phase data inhibitor
differ indic support franchis think investor need
see partnership assign valu program
vertex develop inhibitor treatment pain compani
report data three differ phase trial acut neuropath pain compani indic
expect commerci drug acut neuropath pain special sale forc
interest partner drug develop commerci chronic set
announc potenti global partnership pain key catalyst compani view
like
develop first-gener inhibitor sodium ion
channel subtyp carri pain messag channel target treatment
pain due specif locat sensori neuron
figur inhibit dorsal root ganglion target pain
page
sever compani target sumitomo dainippon
two compani target pain highlight
inhibit success date
figur competit landscap pain inhibit
strh research compani report
data vrtx trial first evid efficaci inhibit
compani shown posit data inhibitor differ
indic highlight aspect challeng demonstr efficaci
across multipl differ type pain mechan
manag view pain multipl indic shown efficaci drug differ set
acut pain follow bunionectomi neuropath pain chronic pain osteoarthr
phase data acut pain trial indic drug compar efficaci
hydrocodon discontinu due side effect profil
acut pain key driver on-going opioid crisi manag note
major treatment acut pain opioid treat hospitals/pain center
 phase data acut pain trial indic drug compar efficaci
hydrocodon discontinu due side effect profil
view compani demonstr compar efficaci risk benefit profil
particularli concern addict potenti drug could open potenti
multi-billion drug opportun
compani expect commerci acut pain set specialti
page
companyproducttargetsmodalityindicationphas developmentbiogen inc vixotrigin raxatrigin sodium voltage-g channel alpha subunit moleculeneuropathyphas inc vixotrigin raxatrigin sodium voltage-g channel alpha subunit moleculepainphas ii voltage-g channel alpha subunit iichromocel voltage-g channel alpha subunit moleculepainphas ibiogen voltage-g channel alpha subunit isumitomo dainippon pharma co voltage-g channel alpha subunit sodium voltage-g channel alpha subunit inc nav blocker voltage-g channel alpha subunit moleculepainphas voltage-g channel alpha subunit iflexion voltage-g channel alpha subunit moleculepainpreclinicalvoyag voltage-g channel alpha subunit viru aav painpreclinicalsiteon voltage-g channel alpha subunit sodium channelpainresearch incorpor
figur studi acut pain bunionectomi
strh research compani report
neuropath pain compani shown stat-sig improv pain scale versu
placebo small phase studi
would demonstr superior approv drug lyrica go
neuropath pain diabet non-diabet compon expect need
figur phase data small fiber neuropathi studi
strh research compani report
osteoarthrit pain studi patient compani show encourag result
talk compani learn monet drug chronic pain
indic expect establish global partnership
chronic pain typic treat primari care doctor commun market
 third area chronic pain market low back pain sciatica also multi-billion
page
acetaminophentri phasephas treatment treatment channel blocker phase studi acut pain complet treatment disconinu due sae arm studi advers event observ patient three qdmean baselin baselin numer rate scale chang baselin numer rate scale nr week group pbo complet treatment patient discontinu treatment due advers event placebo three patient experienc seriou advers event placebo channel blocker small fiber neuropathi phase studi incorpor
figur studi osteoarthrit pain chronic pain
strh research compani report
think opportun chronic pain huge global partnership could
key catalyst vertex pharmaceut
figur limit exist treatment option
page
sequenc phasephas -- washout -- pbopbo -- washout -- pain subscal score dayssafeti profilefrequ sever advers event observ studi similar pbo patient discontinu treatment due treatment period vs pbo treatment period channel blocker phase studi osteoarthrit paintreat effect incorpor
use opioid chronic pain set led public health crisi us
figur opioid crisi implic industri
strh research compani report
drug target pain pathway much success includ ngf
sever compani lilly/pfizer/regeneron/biib invest develop pain drug target
pathway ngf sever hurdl develop drug
either due lack efficaci primarili safeti concern
research indic common treatment-rel side effect anti-ngf therapi
peripher edema arthralgia extrem pain neurosensori symptom paresthesia
hypoesthesia moreov treatment-rel advers event similar anti-ngf therapi
suggest class-specif effect
compani continu develop ngf pain note drug class put hold
continu face sever hurdl develop
page
figur summari ngf drug develop pain
strh research compani report
thesi around vrtx pain franchis center base earli posit data posit risk-benefit
profil signific need non-opioid drug
page
manag compens align investor interest
overal compens plan appear line sharehold interest name execut offic
elig earn incent bonu base individu perform goal well corpor goal
relat product develop advanc clinic studi compens
execut structur around achiev corpor goal mileston year
base subject object perform goal determin board director
figur summari manag compens
page
figur strh vertex
strh research compani report
page
figur million except per share revenu statement figur million except per share franchisecyst fibrosi franchiseww kalydeco sale orkambi sale symdeko sale trikafta sale cf franchis sale corrector deficiencyprob corrector us corrector row sale corrector defici sale corrector defici revenu product rev total product total total vertex guid incom margin interest incom fv deriv incom expens tax rate incom ep ep non- except ep fc consensu jan stock option exp growth incom ep ep share count share count vertex pharmaceut incorpor
figur strh balanc sheet vertex
strh research compani report
page
balanc sheet figur million except per share asset cash cash cash equival receiv expens current current liabilitiesaccount revenu restructur expens current secur term loan current note due relat sale mileston tax payabl current revenu ex restructur expens ex lt tax financ liabil sharehold vertex pharmaceut incorpor
figur strh vertex
strh research compani report
page
flow statement figur million except per share operationsnet non-oper item depreci base compens note discount amort fair valu deriv incom account expens current payabl accru tax payabl oper chang work sale financingproce issuanc payment note payabl long term issuanc common stock employe financ relat vertex pharmaceut incorpor
inc engag busi discov develop manufactur
commerci small molecul drug patient seriou diseas focus develop
commerci therapi treatment cystic fibrosi infecti diseas includ viral
infect influenza bacteri infect autoimmun diseas rheumatoid
arthriti cancer inflammatori bowel diseas neurolog disord includ pain multipl
sclerosi compani found joshua boger headquart boston
rate buy see continu growth due greater uptak cf cystic fibrosi patient
follow recent approv trikafta potenti could treat cf patient
recent reimburs agreement major territori includ eu uk spain australia
franc canada remain outstand key overhang stock potenti price
upsid current model symdeko price trikafta ex-u territori premium
symdeko trikafta ex-u see upsid fv also one highest
growth compani biopharma ep compound-annual-growth-rate consensu versu
biotech large-cap mean ex-bmrn us pharma mean challeng
market predict growth compani may perform better view final potenti global pain
partnership non-oipiod pain drug would upsid model
valuat risk
use dcf arriv pt use discount rate appropri lower-risk larg
cap compani yet diversifi use termin valu believ compani
use capit continu gener revenu assign probabl pipelin risk poor
uptak reimburs trikafta clinic trial failur lack binari event catalyst
compani mention note
page
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
